See What's Inside
Read this FREE issue now
For healthcare professionals only
  • What's on the Horizon with Diabetes Research and Therapy
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Community Videos on Diabetes Health TV

Dance Out Diabetes

Theresa Garnero

Dance Out Diabetes

Research with Pig Islets

Bernhard J. Hering, M.D.

Research with Pig Islets

Novo Nordisk

Page 5
More from ACCORD
Jul 2, 2010 | 
In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment was compared with standard glucose control.
Academia, Biotech and the Pharmaceutical Industry Have Joined Forces to Fight Diabetes
Jun 18, 2010 | 
IMIDIA ("Innovative Medicines Initiative for Diabetes"), a public private consortium funded by the Innovative Medicines Initiative (IMI), announced today the launch of a project focusing on pancreatic islet cell function and survival. Academia, biotech and pharma industry have joined forces to develop biomarkers and tools to pave the way for improved disease management and ultimately provide a cure for diabetes.
DHTV
Popular
Top Rated

Related Community Videos on Diabetes Health TV

Dance Out Diabetes

Theresa Garnero

Dance Out Diabetes

The i-port®

Davida Kruger and KK Patton

The i-port®

Research with Pig Islets

Bernhard J. Hering, M.D.

Research with Pig Islets

FDA Hedges Approval of Long-Acting Byetta, Asks Amylin for More Information
Mar 29, 2010 | 
The U.S. Food and Drug Administration has withheld approval of Bydureon, the once-weekly version of the popular type 2 diabetes drug Byetta.  The agency has asked its manufacturer, Amylin, for more information regarding Bydureon's manufacture, labeling, and risk management plan. It did not, however, request further information on tests of the drug itself-an indication that the agency probably intends to grant marketing permission once it has dotted all the i's and crossed all the t's involved in the approval process.
Starting Treatment Early Doubles Chance of Success for People with Diabetes
Mar 12, 2010 | 
The sooner people with diabetes start taking metformin, the longer the drug remains effective, according to a Kaiser Permanente study published in the March issue of Diabetes Care, a journal of the American Diabetes Association.
Amylin Hopes to Begin U.S. Sales of Long-Acting Byetta Early This Year
Mar 4, 2010 | 
Amylin Pharmaceuticals has announced that it expects to begin selling a once-weekly version of its diabetes drug, Byetta, by the end of the year. The company reports that the FDA is nearing final inspections of its manufacturing plant and could give the go-ahead for U.S. sales in early March.
Diabetes and Pre-Diabetes Cost the U.S. $218 Billion in 2007: En Route to $336 Billion by 2034
Feb 3, 2010 | 
A study commissioned by healthcare company Novo Nordisk has reported that the cost of diabetes and pre-diabetes to the U.S. economy in 2007 was $218 billion. The study, conducted by The Lewin Group, projected that by 2034, the two conditions will cost the economy $336 billion per year.
Novo, Upping the Ante in the Race for an Oral GLP-1 Drug, Tests a Pill Version of Victoza
Feb 1, 2010 | 
Denmark-based Novo Nordisk has begun a Phase 1 trial of a pill form of a GLP-1 drug very similar to its Victoza product. The trial will involve  155 British patients with type 2 diabetes. The test on human subjects, although very early-stage,  puts the company in the lead to develop an oral form of a GLP-1 drug.
Next Page » « Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.